Drug
Indacaterol-glycopyrronium combination clinical trials
Also written QVA149.
- studies test it
- 26
- open now
- 0
- in phase 3
- 20
- first study started
- 2010
How studies write it
Studies that test it under each name
Development codes
- QVA149
- 22
Studies by the year they started
26 studies that test it; most in 2012 (7)
| Year | Studies |
|---|---|
| 2010 | 3 |
| 2011 | 4 |
| 2012 | 7 |
| 2013 | 4 |
| 2014 | 3 |
| 2015 | 4 |
| 2016 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 3
- 20
- Phase 4
- 6
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 26 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses indacaterol-glycopyrronium combination is read from its arms, and is right about nine times in ten.
Testing it · 26
- QVA Mechanistic Efficacy Study (Receptor Effects, Etc)CompletedPhase 4Novartis PharmaceuticalsNCT02634983Written as QVA149
- A Randomized, Multicenter, Open-label, Parallel-group, 12-week Study to Assess the Efficacy and Safety of Switching From Tiotropium to QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) in Symptomatic Mild to Moderate COPD PatientsCompletedPhase 4Novartis PharmaceuticalsNCT02566031Written as Indacaterol and glycopyrronium (QVA149)
- Evaluation of the Efficacy and Safety of QVA149 (110/50 μg o.d.) vs Tiotropium (18 µg o.d.) + Salmeterol/Fluticasone Propionate FDC (50/500 µg b.i.d.) in Patients With Moderate to Severe COPDCompletedPhase 4Novartis PharmaceuticalsNCT02603393Written as QVA149
- Effect of QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) on Cardiac Function in COPD PatientsCompletedPhase 4Novartis PharmaceuticalsNCT02442206Written as QVA149
- A Multicenter, 4-week Crossover (Total Duration 12 Weeks) to Determine the Impact of QVA149 on Nocturnal Oxygen Levels in Chronic Obstructive Pulmonary Disease (COPD)CompletedPhase 4Novartis PharmaceuticalsNCT02233543Written as QVA149
- Efficacy and Safety Study of Indacaterol Maleate/Glycopyrronium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients.CompletedPhase 3Novartis PharmaceuticalsNCT02487498Written as QVA149
- Efficacy and Safety Study of QVA149 in COPD PatientsCompletedPhase 3Novartis PharmaceuticalsNCT02487446Written as QVA149
- Lung Function and Patient Preference With QVA149 vs. Tiotropium in COPD PatientsCompletedPhase 4Novartis PharmaceuticalsNCT02125734Written as QVA149
- Comparison of Long-term Safety of the Combination Product QVA149A Against Placebo and Standard of Care Treatment in Chronic Obstructive Pulmonary Disease Patients With Moderate to Severe Airflow LimitationCompletedPhase 3Novartis PharmaceuticalsNCT01610037Written as QVA149
- QVA vs. Salmeterol/Fluticasone, 52-week Exacerbation Study, FLAME (EFfect of Indacaterol Glycopyronium Vs Fluticasone Salmeterol on COPD Exacerbations)CompletedPhase 3Novartis PharmaceuticalsNCT01782326Written as QVA149
- Randomized, Double-blind, Placebo-controlled, Multicenter, Cross-over Study to Assess the Effects of a 3 Week Therapy Each With QVA149 Versus Placebo on Pulmonary Function and Average Physical Activity Levels in Patients With COPD.CompletedPhase 3Novartis PharmaceuticalsNCT01996319Written as QVA149
- A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow LimitationCompletedPhase 3Novartis PharmaceuticalsNCT01682863Written as QVA149
- A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.CompletedPhase 3Novartis PharmaceuticalsNCT01727141Written as QVA149
- A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow LimitationCompletedPhase 3Novartis PharmaceuticalsNCT01712516Written as QVA149
- A 26-week Treatment Randomized, Double-blind, Double Dummy Study to Assess the Efficacy and Safety of QVA149CompletedPhase 3Novartis PharmaceuticalsNCT01709903Written as QVA149
- The Effect of QVA149 on Health Related Quality of Life in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedPhase 3Novartis PharmaceuticalsNCT01574651Written as QVA149
- Comparison of Safety and Efficacy of the Combination Product QVA149A Against the Concurrent Administration of the Individual Components, QAB149 and NVA237, in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedPhase 3Novartis PharmaceuticalsNCT01529632Written as QVA149
- Long Term Safety and Tolerability of QVA149 Versus Tiotropium in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedPhase 3Novartis PharmaceuticalsNCT01285492Written as QVA149
- The Effect of QVA149 on Patient Reported Dyspnea in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)CompletedPhase 3Novartis PharmaceuticalsNCT01490125Written as QVA149
- Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) ExacerbationsCompletedPhase 3Novartis PharmaceuticalsNCT01120691Written as QVA149
See all 26 studies that test indacaterol-glycopyrronium combination →